Latest Breaking News On - ப்ளூம்பெர்க் சனோஃபி - Page 2 : comparemela.com
Sanofi, GSK Restart Trials on Covid-19 Vaccine After Delay
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Sanofi to Make Millions of BioNTech-Pfizer Vaccine Doses
Bloomberg 1/27/2021 © Bloomberg BioNTech will give Sanofi access to its Frankfurt production facility.
(Bloomberg) Sanofi agreed to produce millions of doses of BioNTech SE and Pfizer Inc.’s coronavirus vaccine in an unusual collaboration to speed vaccination efforts.
The French drugmaker will give BioNTech access to a production facility in Frankfurt, which will start to deliver doses this summer, Sanofi said in a statement Wednesday. The deal will produce more than 125 million doses of the messenger RNA vaccine for the European Union.
Sanofi’s own effort to develop a Covid vaccine has stumbled, meaning it won’t be ready by summer as initially expected. The deal with BioNTech allows Europe to make up for some of the loss. The pact also raised hopes that more pharma giants would throw their manufacturing and distribution weight behind the few coronavirus shots that have proved effective.
Sanofi to Make Millions of BioNTech-Pfizer Vaccine Doses
Bloomberg 1/27/2021 © Bloomberg BioNTech will give Sanofi access to its Frankfurt production facility.
(Bloomberg) Sanofi agreed to produce millions of doses of BioNTech SE and Pfizer Inc.’s coronavirus vaccine in an unusual collaboration to speed vaccination efforts.
The French drugmaker will give BioNTech access to a production facility in Frankfurt, which will start to deliver doses this summer, Sanofi said in a statement Wednesday. The deal will produce more than 125 million doses of the messenger RNA vaccine for the European Union.
Sanofi’s own effort to develop a Covid vaccine has stumbled, meaning it won’t be ready by summer as initially expected. The deal with BioNTech allows Europe to make up for some of the loss. The pact also raised hopes that more pharma giants would throw their manufacturing and distribution weight behind the few coronavirus shots that have proved effective.
Cuomo Says Surge Over; EU, Astra Feud Escalates: Virus Update Bloomberg 1/27/2021 Bloomberg News © Photographer: Jeff Pachoud/AFP via Getty Images A nurse washes a Covid-19 patient at a hospital in Pierre-Benite, France, on Jan. 25.
(Bloomberg) Governor Andrew Cuomo lifted restrictions in most hot spots across New York state, declaring an end to the post-holiday surge in cases and hospitalizations. New York City said it will receive 17,000 additional vaccine shots next week, after the Biden administration boosted deliveries.
The European Union failed to resolve its dispute with AstraZeneca Plc over vaccine supplies, raising the risk of additional delays to the bloc’s sluggish inoculation campaign and putting the drugmaker on a collision course with 27 governments. The quarrel could add another thorn to the tumultuous post-Brexit ties between Britain and the EU.
Sanofi to Buy Antibody Maker Kymab in $1.45 Billion Deal
Bloomberg 1/11/2021 Tim Loh © Photographer: JOEL SAGET/AFP Sanofi has been hunting for acquisitions to bolster its pipeline of new medicines.
(Bloomberg) Sanofi agreed to buy the U.K. monoclonal antibody developer Kymab in a deal worth as much as $1.45 billion to gain experimental medicines for inflammation diseases as well as cancer.
The French drugmaker will obtain global rights to KY1005, a human monoclonal antibody with a new mechanism of action and the potential to treat a variety of disorders, the Paris-based company said in a statement.
Sanofi has been hunting for acquisitions to bolster its pipeline, and the deal continues the company’s pivot toward treatments targeting the immune system. The Kymab agreement comes after Sanofi agreed to spend $3.4 billion for U.S. biotech company Principia Biopharma Inc., which developed a pipeline of drugs known as BTK inhibitors to treat autoimmune di
vimarsana © 2020. All Rights Reserved.